Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + oxaliplatin + docetaxel
- Development stage
- Phase 3
- Lead developer
- Taipei Veterans General Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This drug regimen is a sequential chemotherapy protocol consisting of capecitabine and oxaliplatin (XELOX) followed by docetaxel and capecitabine (TX). It was evaluated by the Taipei Veterans General Hospital for the treatment of unresectable gastric cancer. Capecitabine is an oral fluoropyrimidine carbamate that acts as a prodrug of 5-fluorouracil, inhibiting thymidylate synthase. Oxaliplatin is a third-generation platinum compound that forms DNA adducts, leading to the inhibition of DNA synthesis and transcription. Docetaxel is a taxane that promotes microtubule assembly and inhibits disassembly, resulting in cell cycle arrest. The sequential approach aims to maximize efficacy while managing toxicity in patients with advanced gastric malignancies.
- Other names
- capecitabine + oxaliplatin followed by docetaxel + capecitabine
02
Targets
DNATS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on capecitabine + oxaliplatin + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + oxaliplatin + docetaxel.